96187-75-6

Usage

Uses

Used in Pharmaceutical Industry:
6-Chloro-5-methylisatin is used as a chemical precursor for the synthesis of various pharmaceutical drugs. Its unique structure and properties make it a valuable component in the development of new medications.
Used in Anti-cancer Applications:
In the field of oncology, 6-Chloro-5-methylisatin is utilized as a potential anti-cancer agent. Its biological activity has been the subject of research, with studies indicating its potential to combat cancer cells and contribute to cancer treatment strategies.
Used in Anti-inflammatory Applications:
6-Chloro-5-methylisatin also serves as a potential anti-inflammatory agent. Its ability to modulate inflammatory responses makes it a candidate for the development of treatments for various inflammatory conditions.
Used in Research and Development:
6-CHLORO-5-METHYLISATIN is extensively used in research and development for exploring its therapeutic properties and potential applications in medicine. Ongoing studies aim to uncover its full range of capabilities and optimize its use in healthcare.

Upstream product

• 95-74-9 3-chloro-p-toluidine 
• 155184-79-5 N-(3-chloro-4-methyl-phenyl)-2-hydroxyimino-acetamide 
• 7745-89-3 3-chloro-4-methylaniline hydrochloride 

Downstream Products

• 155184-81-9 2-amino-5-methyl-4-chlorobenzoic acid 

Relevant academic research and scientific papers

Synthesis of substituted tryptanthrin via aryl halides and amines as antitumor and anti-MRSA agents

The natural alkaloid, tryptanthrin (indolo[2,1-b]quinazoline-6,12-dione), and its analogues are found to exhibit potent antitumor and anti-MRSA activities. An efficient and convenient method has been developed for the synthesis of tryptanthrin D-ring derivatives through the reaction of substituted tryptanthrins and secondary amines in moderate to good yields. Some of the new compounds exhibited antitumor activities against the human tumor cell lines A549, HCT116 and MDA-MB-231, with mean IC50 values at low micromolar levels. In addition, some of the compounds showed excellent anti-MRSA activities and were more effective than vancomycin, with MIC values of 0.31–1.25 μg/mL for Mu50,RN4220, and Newman strains.

Synthesis and in vitro antitumor activity of thiophene analogues of 5-chloro-5,8-dideazafolic acid and 2-methyl-2-desamino-5-chloro-5,8-dideazafolic acid

N-[5-[N-(2-Amino-5-chloro-3,4-dihydro-4-oxoquinazolin-6-yl)methylamino]-2- thenoyl]-L-glutamic acid (6) and N-[5-[N-(5-chloro-3,4-dihydro-2-methyl-4-oxoquinazolin-6-yl)methylamino]-2- thenoyl]-L-glutamic acid (7), the first reported thiophene analogues of 5-chloro-5,8-dideazafolic acid, were synthesized and tested as inhibitors of tumor cell growth in culture. 4-Chloro-5-methylisatin (10) was converted stepwise to methyl 2-amino-5-methyl-6-chlorobenzoate (22) and 2-amino-5-chloro-3,4-dihydro-6-methyl-4-oxoquinazoline (19). Pivaloylation of the 2-amino group, followed by NBS bromination, condensation with di-tert-butyl N-(5-amino-2-thenoyl)-L-glutamate (28), and stepwise cleavage of the protecting groups with ammonia and TFA yielded 6. Treatment of 9 with acetic anhydride afforded 2,6-dimethyl-5-chlorobenz[1,3-d]oxazin-4-one (31), which on reaction with ammonia, NaOH was converted to 2,6-dimethyl-5-chloro-3,4-dihydroquinazolin-4-one (33). Bromination of 33, followed by condensation with 28 and ester cleavage with TFA, yielded 7. The IC50 of 6 and 7 against CCRF-CEM human leukemic lymphoblasts was 1.8±0.1 and 2.1±0.8 μM, respectively.